
United States · Health startup
EyeNetra, Inc. is a health technology company based in Cambridge, Massachusetts, founded in 2011.
Funding reportedLast round: Series A
EyeNetra, Inc. is a health technology company based in Cambridge, Massachusetts, founded in 2011.
The company develops smartphone-powered vision testing tools designed for mobile refractive clinics, screening events, and workplace testing. Its core products include the NETRA auto refractor, lensometer, and phoropter, which together create a comprehensive refraction system for accurately screening nearsightedness, farsightedness, and astigmatism. In addition to hardware, EyeNetra offers the Insight Portal, a cloud-based platform that enhances Electronic Medical Record (EMR) management for patients and mobile clinics. The Blink vision testing service employs traveling optometrists to provide convenient eye tests. EyeNetra serves a diverse range of customers, including mobile eye care professionals, concierge practices, health care centers, global corporations, independent optometry practices, and underserved communities. The company aims to lead the Mobile Health (mHealth) revolution by integrating mobile eye diagnostics with a cloud platform that connects patients to various eye care providers.
Funding, as reported
From the SEC filings it signed: 2 on the team.
On the board, as filediEuan Robert ThomsonJim Robert McGrannRamesh RaskarSrikanth Nadhamuni
What they build
Known for
health careconsumersdistributionlensometerai-based tele-refractioncontact lensesopen source vision technologyopticianryinformation technology & serviceslow-cost eye diagnosticsteleoptometryphoropteroptometry & ophthalmologyauto-refractorhospital & health caremobile clinic equipment
Built with from their website
Google Tag ManagerWordPress.orgGoogle CloudWOWFont AwesomeYouTubeGitHubGoogle WorkspaceViewport MetaGoogle Play
VarnishGoogle Cloud HostingGoogle MeetMySQLMobile FriendlyBootstrapGitHub PagesOpen Graph
Add your raise, your deck and your story, and put EyeNetra, Inc. in front of investors. Or tell us what we have wrong.